Skip to main content
Canntab Therapeutics Limited logo

Canntab Therapeutics Limited — Investor Relations & Filings

Ticker · CTABF ISIN · CA1377991023 LEI · 529900979I76WYMMKK84 CSE Manufacturing
Open in API
Filings indexed 76 across all filing types
Latest filing 2024-04-15 Capital/Financing Update
Country CA Canada
Listing CSE CTABF

About Canntab Therapeutics Limited

https://canntab.ca/

Canntab Therapeutics Limited is a phytopharmaceutical company specializing in the research, development, and manufacturing of advanced pharmaceutical grade cannabis formulations. The company focuses on innovative solid oral dosage delivery methods, positioning itself as a leader in this medical segment. Its product portfolio includes patented Instant Release (IR) and Extended Release (XR) tablets containing precise doses of THC, CBD, and other Cannabinoids. These formulations are designed to offer medical simplicity and enhanced dosage control for individuals seeking health and wellness solutions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a private placement financing by Canntab Therapeutics Limited. It discusses raising capital through a private placement of common shares, the use of proceeds, and regulatory context including a partial revocation order from the Ontario Securities Commission. There are no financial statements or detailed financial data presented, nor is this a full report or earnings release. The document focuses on capital raising and regulatory compliance related to financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 5590 characters, which is sufficient for a detailed announcement but does not contain financial statements or management discussion. Hence, the classification is CAP with high confidence.
2024-04-15 English
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and includes detailed information about a material change at Canntab Therapeutics Limited, including a summary and full description of the change, dates, and contact information. It references a news release disseminated on November 22, 2022, and discusses strategic business updates, lease issues, licensing, and patents. The document is a regulatory filing form specific to material changes under Canadian securities law (NI 51-102). It is not an annual report, earnings release, or management discussion but a formal material change report filed with regulatory authorities. The length (over 14,000 characters) and detailed content confirm it is the actual report, not just an announcement. Therefore, the document fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-11-25 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release announcing Canntab Therapeutics Limited's entrance into the Nova Scotia cannabis market, specifically the shipment and availability of their THC tablets at the Nova Scotia Liquor Corporation. It contains no financial statements, no detailed financial performance data, no regulatory filings, no voting results, no management or board changes, no audit information, and no earnings data. It is a corporate announcement about product delivery and market expansion. The document length is 6904 characters, which is relatively short and typical for a press release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention any report being published or attached. The content is best classified as a Capital/Financing Update (CAP) because it relates to company business development and market expansion, which is often covered under capital or financing updates in the context of corporate announcements about product launches or market entries. Therefore, the most appropriate classification is CAP with high confidence.
2022-08-22 English
News release - English.pdf
Regulatory Filings
2022-08-02 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate, signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended February 28, 2022. It explicitly states it is a certification of interim filings, not the filings themselves, and contains no actual financial data or substantive financial analysis. The document is short (3002 characters) and primarily an officer certification. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS), not as the interim report (IR) itself.
2022-04-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate, signed by the CFO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended February 28, 2022. It explicitly states it is a certification related to interim filings, not the filings themselves. The document is short (3011 characters) and primarily an officer certification letter. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS), not as the interim report itself (IR).
2022-04-29 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.